PEGylated liposomes incorporated with nonionic surfactants as an apomorphine delivery system targeting the brain: In vitro release and in vivo real-time imaging

Current Nanoscience

Volumn 7, Issue 2, 2011, Pages 191-199

  Hsu, Shu Hui ^a   Al Suwayeh, Saleh A ^b   Chen, Chih Chieh ^c   Chi, Chen Hsien ^c   Fang, Jia You ^b,c,d  

^a CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

Apomorphine; Blood brain barrier; Brain targeting; Drug delivery systems; PEGylated liposomes

Indexed keywords

APOMORPHINE; AQUEOUS SOLUTIONS; BIOLUMINESCENCE IMAGING; BLOOD-BRAIN BARRIER; BRAIN UPTAKE; CLINICAL APPLICATION; DELIVERY SYSTEMS; DRUG DELIVERY SYSTEMS; DRUG ENCAPSULATION; IN-VITRO; IN-VIVO; MEAN SIZE; NEW OPPORTUNITIES; PARKINSON'S DISEASE; PEGYLATED LIPOSOMES; POSITIVE SURFACE CHARGE; REALTIME IMAGING; RELEASE BEHAVIORS; TWEEN 80; VESICLE SIZE;

BLOOD; DISEASES; DRUG DELIVERY; ENCAPSULATION; NONIONIC SURFACTANTS; PHOSPHOLIPIDS; PLASMA STABILITY; ZETA POTENTIAL;

LIPOSOMES;

APOMORPHINE; LIPOSOME; MACROGOL; OCTADECYLAMINE; POLYOXYETHYLENE STEARYL ETHER; POLYSORBATE 80;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS SOLUTION; ARTICLE; BIOLUMINESCENCE; BLOOD BRAIN BARRIER; BRAIN; COMPARATIVE STUDY; CONTROLLED STUDY; DEGENERATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STABILITY; DRUG TARGETING; DRUG UPTAKE; ENCAPSULATION; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PARTICLE SIZE; PERMEABILITY; PRIORITY JOURNAL; RAT; SLOW DRUG RELEASE; ZETA POTENTIAL;

RATTUS;

EID: 79951742460     PISSN: 15734137     EISSN: None     Source Type: Journal    
DOI: 10.2174/157341311794653686     Document Type: Article

References (49)

1. Stacy, M.; Silver, D. Apomorphine for the acute treatment of "off" episodes in Parkinson's disease. Parkinson. Relat. Disord., 2008, 14, 85-92.
2. Picada, J.N.; Maris, A.F.; Ckless, K.; Salvador, M.; Khromov-Borisov, N.N.; Henriques, J.A.P. Differential mutagenic, antimutagenic and cytotoxic responses induced by apomorphine and its oxidation product, 8-oxo-apomorphine-semiquinone, in bacteria and yeast. Mutat. Res., 2003, 539, 29-41.
3. Danhof, M.; Van der Geest, R.; Van Laar, T.; Boddé, H.E. An integrated pharmacokinetic-pharmacodynamic approach to optimization of R-apomorphine delivery in Parkinson's disease. Adv. Drug Deliv. Rev., 1998, 33, 203-263.
4. Subramony, J.A. Apomorphine in dopaminergic therapy. Mol. Pharm., 2006, 3, 380-385.
5. Visser, C.C.; Stevanovi, S.; Voorwinden, L.H.; van Bloois, L.; Gaillard, P.J.; Danhof, M.; Crommelin, D.J.A.; de Boer, A.G. Targeting liposomes with protein drugs to the blood-brain barrier in vitro. Eur. J. Pharm. Sci., 2005, 25, 299-305.
6. Okura, T.; Ito, R.; Ishiguro, N.; Tamai, I.; Deguchi, Y. Blood-brain barrier transport of pramipexole, a dopamine D2 agonist. Life Sci., 2007, 80, 1564-1571.
7. Lockmam, P.R.; Koziara, J.; Roder, K.E.; Paulson, J.; Abbruscato, T.J.; Mumper, R.J.; Allen, D.D. In vivo and in vitro assessment of baseline blood-brain barrier parameters in the presence of novel nanoparticles. Pharm. Res., 2003, 20, 705-713.
8. Afergan, E.; Epstein, H.; Dahan, R.; Koroukhov, N.; Rohekar, K.; Darenberg, H.D.; Golomb, G. Delivery of serotonin to the brain by monocytes following phagocytosis of liposomes. J. Control. Release, 2008, 132, 84-90.
9. Tiwari, S.B.; Amiji, M.M. A review of nanocarrier-based CNS delivery systems. Curr. Drug Deliv., 2006, 3, 219-232.
10. Parveen, S.; Sahoo, S.K. Polymeric nanoparticles for cancer therapy. J. Drug Target., 2008, 16, 108-123.
11. Zhang, X.; Xie, J.; Li, S.; Wang, X.; Hou, X. The study on brain targeting of the amphotericin B liposomes. J. Drug Target., 2003, 11, 117-122.
12. Fang, J.Y.; Hwang, T.L.; Huang, Y.L. Liposomes as vehicles for enhancing drug delivery via skin routes. Curr. Nanosci., 2006, 2, 55-70.
13. Tosi, G.; Costantino, L.; Ruozi, B.; Forni, F.; Vandelli, M.A. Polymeric nanoparticles for the drug delivery to the central nervous system. Exp. Opin. Drug Deliv., 2008, 5, 155-174.
14. Hwang, T.L.; Lin, Y.K.; Chi, C.H.; Huang, T.H.; Fang, J.Y. Development and evaluation of perfluorocarbon nanobubbles for apomorphine delivery. J. Pharm. Sci., 2009, 98, 3735-3747.
15. Thomas, V.; Kumari, T.V.; Jayabalan, M. In vitro studies on the effect of Physical cross-linking on the biological performance of aliphatic poly(urethane urea) for blood contact applications. Macromolecules, 2001, 2, 588-596.
16. Chen, X.; Zhang, X.; Larson, C.S.; Baker, M.S.; Kaufman, D.B. In vivo bioluminescence imaging of transplanted islets and early detection of graft rejection. Transplantation, 2006, 81, 1421-1427.
17. Moghimi, S.M.; Hunter, A.C.; Murray, J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev., 2001, 53, 283-318.
18. Jallouli, Y.; Paillard, A.; Chang, J.; Sevin, E.; Betbeder, D. Influence of surface charge and inner composition of porous nanoparticles to cross blood-brain barrier in vitro. Int. J. Pharm., 2007, 244, 103-109.
19. Harris, J.M.; Chess, R.B. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov., 2003, 2, 214-221.
20. Béduneau, A.; Hindré, F.; Clavreul, A.; Leroux, J.; Saulinier, P.; Benoit, J. Brain targeting using novel lipid nanovectors. J. Control. Release, 2008, 126, 33-49.
21. Hung, C.F.; Fang, C.L.; Liao, M.H.; Fang, J.Y. The effect of oil components on the physicochemical properties and drug delivery of emulsions: tocol emulsion versus lipid emulsion. Int. J. Pharm., 2007, 335, 193-202.
22. Wang, J.J.; Sung, K.C.; Yeh, C.H; Fang, J.Y. The delivery and antinociceptive effects of morphine and its ester prodrugs from lipid emulsions. Int. J. Pharm., 2008, 353, 95-104.
23. Lockman, Oyewumi, M.O.; Koziara, J.M.; Roder, K.E.; Mumper, R.J.; Allen, D.D. Brain uptake of thiamine-coated nanoparticles. J. Control. Release, 2003, 93, 271-282.
24. Kreuter, J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev., 2001, 47, 65-81.
25. Reimold, I.; Domke, D.; Bender, J.; Seyfried, C.A.; Radunz, H.; Fricker, G. Delivery of nanoparticles to the brain detected by fluorescence microscopy. Eur. J. Pharm. Biopharm., 2008, 70, 627-632.
26. El Maghraby, G.M.M.; Williams, A.C.; Barry, B.W. Interactions of surfactants (edge activators) and skin penetration enhancers with liposomes. Int. J. Pharm., 2004, 276, 143-161.
27. Dadashzadeh, S.; Vali, A.M.; Rezaie, M. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats. Int. J. Pharm., 2008, 353, 251-259.
28. Wilson, B.; Samanta, M.K.; Santhi, K.; Kumar, K.P.S.; Paramakrishnan, N.; Suresh, B. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease. Brain Res., 2008, 1200, 159-168.
29. Müller, R.H.; Jacobs, C.; Kayser, O. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev., 2001, 47, 3-19.
30. Wang, J.J.; Sung, K.C.; Hu, O.Y.P.; Yeh, C.H.; Fang, J.Y. Submicron lipid emulsion as a drug delivery system for nalbuphine and its prodrugs. J. Control. Release, 2006, 115, 140-149.
31. Hashizaki, K.; Taguchi, H.; Itoh, C.; Sakai, H.; Abe, M.; Saito, Y.; Ogawa, N. Effects of poly(ethylene glycol) (PEG) concentration on the permeability of PEG-grafted liposomes. Chem. Pharm. Bull., 2005, 5, 27-31.
32. Simard, P.; Hoarau, D.; Khalid, M.N.; Roux, E.; Leroux, J. Preparation and in vivo evaluation of PEGylated spherulite formulations. Biochim. Biophys. Acta, 2005, 1715, 37-48.
33. Zhang, J.Q.; Liu, J.; Li, X.L.; Jasti, B.R. Preparation and characterization of solid lipid nanoparticles containing silibinin. Drug Deliv., 2007, 14, 381-387.
34. El Maghraby, G.M.M.; Williams, A.C.; Barry, B.W. Oestradiol skin delivery from ultradeformable liposomes: refinement of surfactant concentration. Int. J. Pharm., 2000, 196, 63-74.
35. Ishii, F.; Nagasaka, Y. Interaction between erythrocytes and free phospholipids as an emulsifying agent in fat emulsions or drug carrier emulsions for intravenous injections. Colloid Surf. B Biointerface, 2004, 37, 43-47.
36. Krzyzaniak, J.F.; Raymond, D.M.; Yalkowsky, S.H. Lysis of human blood cells 2: Effect of contact time on cosolvent induced hemolysis. Int. J. Pharm., 1997, 152, 193-200.
37. Constandinides, P.P.; Lambert, K.J.; Tustian, A.K.; Schneider, B.; Lalji, S.; Ma, B.; Wentzel, W.; Kessler, D.; Worah, D.; Quay, S.C. Formulation development and antitumor activity of a filter-sterilizable emulsion of paclitaxel. Pharm. Res. 2000, 17, 175-182.
38. Krauze, M.T.; Forsayeth, J.; Park, J.W.; Bankiewicz, K.S. Real-time imaging and quantification of brain delivery of liposomes. Pharm. Res., 2006, 23, 2493-2504.
39. Webb, M.S.; Saxon, D.; Wong, F.M.; Lim, H.J.; Wang, Z.; Bally, M.B.; Choi, P.R.; Cullis, L.S.L.; Mayer, L.D. Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine. Biochim. Biophys. Acta, 1998, 1372, 272-282.
40. Drummond, D.C.; Meyer, O.; Hong, K.; Kirpotin, D.B.; Papahadjopoulos, D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev., 1999, 51, 691-743.
41. Ugwoke, M.I.; Kaufmann, G.; Verbeke, N.; Kinget, R. Intranasal bioavailability of apomorphine from carboxymethylcellulose-based drug delivery systems. Int. J. Pharm., 2000, 202, 125-131.
42. Ingram, W.M.; Priston, M.J.; Sewell, G.J. Improved assay for R(-)-apomorphine with application to clinical pharmacokinetic studies in Parkinson's disease. J. Chromatogr. B, 2006, 831, 1-7.
43. Vasir, J.K.; Reddy, M.K.; Labhasetwar, V.D. Nanosystems in drug targeting: opportunities and challenges. Curr. Nanosci., 2005, 1, 47-64.
44. Kuo, C.; Coquoz, O.; Troy, T.L.; Xu, H.; Rice, B.W. Three-dimensional reconstruction of in vivo bioluminescent sources based on multispectral imaging. J. Biomed. Opt., 2007, 12, 024007.
45. Negrin, R.S.; Contag, C.H. In vivo imaging using bioluminescence: a tool for probing graft-versus-host disease. Nat. Rev. Immunol., 2006, 6, 484-490.
46. MacKay, J.A.; Deen, D.F.; Szoka Jr, F.C. Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating. Brain Res., 2005, 1035, 139-153.
47. Koziara, J.M.; Lockman, P.R.; Allen, D.D.; Mumper, R.J. In situ blood-brain barrier transport of nanoparticles. Pharm. Res., 2003, 20, 1772-1778.
48. Rao, K.S.; Reddy, M.K.; Horning, J.L.; Labhasetwar, V. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials, 2008, 29, 4429-4438.
49. Xie, Y.; Ye, L.; Zhang, X.; Cui, W.; Lou, J.; Nagai, T.; Hou, X. Transport of nerve growth factor encapsulated into liposomes across the blood-brain barrier: in vitro and in vivo studies. J. Control. Release, 2005, 105, 106-119.